Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times
暂无分享,去创建一个
Abdus S Wahed | Peter F Thall | Peter Müller | Yanxun Xu | P. Müller | P. Thall | Yanxun Xu | A. Wahed
[1] Michael R. Kosorok,et al. Causal nearest neighbor rules for optimal treatment regimes , 2017, 1711.08451.
[2] Wenbin Lu,et al. Optimal treatment regimes for survival endpoints using a locally-efficient doubly-robust estimator from a classification perspective , 2017, Lifetime data analysis.
[3] Wenbin Lu,et al. Change-Plane Analysis for Subgroup Detection and Sample Size Calculation , 2017, Journal of the American Statistical Association.
[4] Thomas A Murray,et al. Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer , 2017, Journal of the American Statistical Association.
[5] Michael R Kosorok,et al. Residual Weighted Learning for Estimating Individualized Treatment Rules , 2015, Journal of the American Statistical Association.
[6] Wenbin Lu,et al. On estimation of optimal treatment regimes for maximizing t‐year survival probability , 2014, Journal of the Royal Statistical Society. Series B, Statistical methodology.
[7] P. Diggle,et al. Latent Variable Modeling and Applications to Causality , 2017 .
[8] Peter F Thall,et al. Bayesian group sequential clinical trial design using total toxicity burden and progression‐free survival , 2016, Journal of the Royal Statistical Society. Series C, Applied statistics.
[9] Trippa Lorenzo,et al. Bayesian Nonparametric Estimation for Dynamic Treatment Regimes With Sequential Transition Times Comment , 2016 .
[10] Eric B. Laber,et al. Tree-based methods for individualized treatment regimes. , 2015, Biometrika.
[11] Marie Davidian,et al. Using decision lists to construct interpretable and parsimonious treatment regimes , 2015, Biometrics.
[12] Peter F Thall,et al. Bayesian Dose-Finding in Two Treatment Cycles Based on the Joint Utility of Efficacy and Toxicity , 2015, Journal of the American Statistical Association.
[13] Donglin Zeng,et al. New Statistical Learning Methods for Estimating Optimal Dynamic Treatment Regimes , 2015, Journal of the American Statistical Association.
[14] Iven Van Mechelen,et al. A Novel Method for Estimating Optimal Tree-Based Treatment Regimes in Randomized Clinical Trials , 2015 .
[15] Eric B. Laber,et al. Doubly Robust Learning for Estimating Individualized Treatment with Censored Data. , 2015, Biometrika.
[16] Wenting Cheng,et al. Reader reaction to “A robust method for estimating optimal treatment regimes” by Zhang et al. (2012) , 2015, Biometrics.
[17] Xuming He,et al. Inference for Subgroup Analysis With a Structured Logistic-Normal Mixture Model , 2015 .
[18] Eric B. Laber,et al. Interactive model building for Q-learning. , 2014, Biometrika.
[19] Nema Dean,et al. Q-Learning: Flexible Learning About Useful Utilities , 2013, Statistics in Biosciences.
[20] Holly Janes,et al. Combining biomarkers to optimize patient treatment recommendations , 2014, Biometrics.
[21] C. Carvalho,et al. Decoupling Shrinkage and Selection in Bayesian Linear Models: A Posterior Summary Perspective , 2014, 1408.0464.
[22] Eric B. Laber,et al. Inference about the expected performance of a data-driven dynamic treatment regime , 2014, Clinical trials.
[23] Anastasios A. Tsiatis,et al. Q- and A-learning Methods for Estimating Optimal Dynamic Treatment Regimes , 2012, Statistical science : a review journal of the Institute of Mathematical Statistics.
[24] Eric B. Laber,et al. Dynamic treatment regimes: Technical challenges and applications , 2014 .
[25] Marie Davidian,et al. Robust estimation of optimal dynamic treatment regimes for sequential treatment decisions. , 2013, Biometrika.
[26] Yingqi Zhao,et al. Inference for Optimal Dynamic Treatment Regimes Using an Adaptive m‐Out‐of‐n Bootstrap Scheme , 2013, Biometrics.
[27] Peter F Thall,et al. Using Joint Utilities of the Times to Response and Toxicity to Adaptively Optimize Schedule–Dose Regimes , 2013, Biometrics.
[28] Abdus S Wahed,et al. Evaluating joint effects of induction–salvage treatment regimes on overall survival in acute leukaemia , 2013, Journal of the Royal Statistical Society. Series C, Applied statistics.
[29] Riten Mitra,et al. Bayesian Nonparametric Inference - Why and How. , 2013, Bayesian analysis.
[30] Eric B. Laber,et al. A Robust Method for Estimating Optimal Treatment Regimes , 2012, Biometrics.
[31] Donglin Zeng,et al. Estimating Individualized Treatment Rules Using Outcome Weighted Learning , 2012, Journal of the American Statistical Association.
[32] Peter F Thall,et al. Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer , 2012, Journal of the American Statistical Association.
[33] Stephen G. Walker,et al. A Bayesian nonparametric causal model , 2012 .
[34] M. Kosorok,et al. Q-LEARNING WITH CENSORED DATA. , 2012, Annals of statistics.
[35] Min Zhang,et al. Estimating optimal treatment regimes from a classification perspective , 2012, Stat.
[36] Jennifer L. Hill,et al. Bayesian Nonparametric Modeling for Causal Inference , 2011 .
[37] Tristan Zajonc,et al. Bayesian Inference for Dynamic Treatment Regimes: Mobility, Equity, and Efficiency in Student Tracking , 2010 .
[38] J. Robins,et al. The International Journal of Biostatistics CAUSAL INFERENCE Dynamic Regime Marginal Structural Mean Models for Estimation of Optimal Dynamic Treatment Regimes , Part I : Main Content , 2011 .
[39] Carl E. Rasmussen,et al. Gaussian processes for machine learning , 2005, Adaptive computation and machine learning.
[40] A. P. Dawid,et al. Regression and Classification Using Gaussian Process Priors , 2009 .
[41] Radford M. Neal. Regression and Classification Using Gaussian Process Priors , 2009 .
[42] M. Kosorok,et al. Reinforcement learning design for cancer clinical trials , 2009, Statistics in medicine.
[43] J. Robins,et al. Estimation and extrapolation of optimal treatment and testing strategies , 2008, Statistics in medicine.
[44] Peter F Thall,et al. Bayesian and frequentist two‐stage treatment strategies based on sequential failure times subject to interval censoring , 2007, Statistics in medicine.
[45] P. Thall,et al. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. , 2007, Journal of the National Cancer Institute.
[46] J Q Shi,et al. Gaussian Process Functional Regression Modeling for Batch Data , 2007, Biometrics.
[47] Erica E M Moodie,et al. Demystifying Optimal Dynamic Treatment Regimes , 2007, Biometrics.
[48] Susan A Murphy,et al. Customizing treatment to the patient: adaptive treatment strategies. , 2007, Drug and alcohol dependence.
[49] S. Murphy,et al. Developing adaptive treatment strategies in substance abuse research. , 2007, Drug and alcohol dependence.
[50] M. J. van der Laan,et al. The International Journal of Biostatistics Causal Effect Models for Realistic Individualized Treatment and Intention to Treat Rules , 2011 .
[51] G. Bernstein,et al. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.
[52] J. McClellan,et al. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. , 2007, Journal of the American Academy of Child and Adolescent Psychiatry.
[53] K. Hirano,et al. Asymptotics for Statistical Treatment Rules , 2009 .
[54] A. Tsiatis. Semiparametric Theory and Missing Data , 2006 .
[55] Anastasios A. Tsiatis,et al. Semiparametric efficient estimation of survival distributions in two-stage randomisation designs in clinical trials with censored data , 2006 .
[56] S. Murphy,et al. An experimental design for the development of adaptive treatment strategies , 2005, Statistics in medicine.
[57] P. Rothwell. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation , 2005, The Lancet.
[58] V. De Gruttola,et al. Reader Reaction , 2004 .
[59] P. Lavori,et al. Placebo‐free designs for evaluating new mental health treatments: the use of adaptive treatment strategies , 2004, Statistics in medicine.
[60] P. Thall,et al. Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs , 2004, Biometrics.
[61] Sara T Brookes,et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. , 2004, Journal of clinical epidemiology.
[62] James M. Robins,et al. Optimal Structural Nested Models for Optimal Sequential Decisions , 2004 .
[63] S. Murphy,et al. Optimal dynamic treatment regimes , 2003 .
[64] H. Sung,et al. Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials , 2002 .
[65] Marie Davidian,et al. Estimation of Survival Distributions of Treatment Policies in Two‐Stage Randomization Designs in Clinical Trials , 2002, Biometrics.
[66] J M Robins,et al. Marginal Mean Models for Dynamic Regimes , 2001, Journal of the American Statistical Association.
[67] Lancelot F. James,et al. Gibbs Sampling Methods for Stick-Breaking Priors , 2001 .
[68] J. Robins,et al. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.
[69] J. Robins,et al. Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.
[70] Radford M. Neal. Markov Chain Sampling Methods for Dirichlet Process Mixture Models , 2000 .
[71] H. Sung,et al. Evaluating multiple treatment courses in clinical trials. , 2000, Statistics in medicine.
[72] Philip W. Lavori,et al. A design for testing clinical strategies: biased adaptive within‐subject randomization , 2000 .
[73] J. Robins,et al. Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models , 1999 .
[74] P F Thall,et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. , 1999, Blood.
[75] Christopher K. I. Williams. Prediction with Gaussian Processes: From Linear Regression to Linear Prediction and Beyond , 1999, Learning in Graphical Models.
[76] S. MacEachern,et al. Estimating mixture of dirichlet process models , 1998 .
[77] James M. Robins,et al. Causal Inference from Complex Longitudinal Data , 1997 .
[78] Geoffrey E. Hinton,et al. Bayesian Learning for Neural Networks , 1995 .
[79] J. Robins,et al. Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers , 1992 .
[80] J. Wittes,et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.
[81] J. Sethuraman. A CONSTRUCTIVE DEFINITION OF DIRICHLET PRIORS , 1991 .
[82] D. Rubin. [On the Application of Probability Theory to Agricultural Experiments. Essay on Principles. Section 9.] Comment: Neyman (1923) and Causal Inference in Experiments and Observational Studies , 1990 .
[83] Aad Van Der Vbart,et al. ON DIFFERENTIABLE FUNCTIONALS , 1988 .
[84] C. N. Morris,et al. The calculation of posterior distributions by data augmentation , 1987 .
[85] J. Robins. Addendum to “a new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect” , 1987 .
[86] J. Robins. A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect , 1986 .
[87] A. O'Hagan,et al. Curve Fitting and Optimal Design for Prediction , 1978 .
[88] Donald B. Rubin,et al. Bayesian Inference for Causal Effects: The Role of Randomization , 1978 .
[89] T. Ferguson. A Bayesian Analysis of Some Nonparametric Problems , 1973 .